ASCO Annual Meeting | Conference

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

May 31st 2020

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

Cabozantinib/Atezolizumab Combo Shows Promise in Previously Treated Urothelial Carcinoma

May 31st 2020

The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated promising objective responses in patients with urothelial carcinoma who progressed after receiving platinum-containing chemotherapy.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL

May 31st 2020

Axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors

May 31st 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment

May 31st 2020

Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.

Apalutamide Plus ADT Leads to Significantly Improved Outcomes in Nonmetastatic CRPC

May 31st 2020

Results from the phase III SPARTAN trial showed that apalutamide plus androgen deprivation therapy significantly improved overall survival when compared with ADT plus placebo in patients with nonmetastatic castration-resistant prostate cancer.

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

May 30th 2020

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Encorafenib/Binimetinib Combo Continues to Show Survival Benefits in BRAF V600-Mutant Melanoma

May 30th 2020

The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.

CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma

May 30th 2020

An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.

Update Sustains OS Benefit With Encorafenib/Cetuximab Regimens in BRAF+ mCRC

May 30th 2020

The latest results from the phase 3 BEACON CRC study continued to show an overall survival benefit for encorafenib plus cetuximab with or without binimetinib compared with cetuximab plus irinotecan-containing regimens in patients with BRAF V600E–mutated metastatic colorectal cancer.

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer

May 30th 2020

Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer.

AMG 330 Shows Promise in Treating Relapsed/Refractory AML

May 30th 2020

Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia, with cytokine release syndrome as the most frequent and expected adverse event.

5-Year Follow-Up of COMBI-AD Confirms Long-Term RFS Benefit With Dabrafenib/Trametinib in BRAF+ Melanoma

May 30th 2020

Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.

Pembrolizumab Doubles 24-Month PFS2 in PD-L1 HNSCC

May 30th 2020

Treatment with pembrolizumab improved progression-free survival after subsequent therapy for patients with PD-L1–positive, relapsed/refractory head and neck squamous cell carcinoma.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Updated AVANOVA2 Survival Data Further Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer

May 30th 2020

Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone.

HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer

May 30th 2020

Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.

Pembrolizumab Shows Superior PFS in Relapsed/Refractory Classical Hodgkin Lymphoma

May 30th 2020

Treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma.

Mirvetuximab Soravtansine Combination Shows Positive Response, Tolerability in Ovarian Cancer

May 30th 2020

Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status with a favorable tolerability profile.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas

May 30th 2020

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas.